We recently compiled a list of the 10 Most Undervalued Dow Stocks to Buy Now. Amgen Inc. is one of the most undervalued ...

On June 17, 2025, Regeneron Pharmaceuticals, Inc. (“Regeneron”) filed another complaint against Amgen Inc. (“Amgen”) under the BPCIA, alleging that Amgen’s aflibercept biosimilar, PAVBLU®, infringes U ...

On February 4, 2025, HyClone Laboratories, LLC (“HyClone”), a cell culture media supplier, filed a Motion to Quash a subpoena issued by Amgen, Inc. (“Amgen”). The underlying subpoena was issued in ...

14 January 2025, Bavaria, Munich: The company logo and the lettering of the biotechnology company Amgen can be seen on the facade of the company's headquarters in Munich (Bavaria) on January 14, 2025.

Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4), Amgen (NASDAQ:AMGN), Merck (NYSE:MRK) and Pfizer (NYSE:PFE) released ...

Amgen (NASDAQ:AMGN) is preparing to release its quarterly earnings on Tuesday, 2026-02-03. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect Amgen ...

Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The company has been recording consistently strong top-line performance. Amgen ...

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line. In 2024, when ...

“Amgen’s takeaway is simple yet profound: The current system is working, and innovation is benefiting actual patients.” The ongoing policy debate about pharmaceutical and biologic patents has been ...

Amgen's weight management candidate looks very promising. The large biotech boasts a deep pipeline beyond that segment. Amgen's dividend looks great, and the stock is reasonably valued. Even so, there ...